NBIX – Neurocrine Biosciences, Inc.
NBIX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.34
Margin Of Safety %
Put/Call OI Ratio
1.01
EPS Next Q Diff
-0.03
EPS Last/This Y
5.29
EPS This/Next Y
2.09
Price
163.35
Target Price
211.77
Analyst Recom
1.42
Performance Q
9.24
Upside
46.3%
Beta
0.38
Ticker: NBIX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-14 | NBIX | 172.01 | 0.79 | 1.52 | 12186 |
| 2026-07-15 | NBIX | 171.95 | 0.81 | 1.73 | 12313 |
| 2026-07-16 | NBIX | 171.45 | 0.82 | 0.07 | 12438 |
| 2026-07-17 | NBIX | 170.79 | 0.82 | 1.52 | 12455 |
| 2026-07-20 | NBIX | 172.97 | 0.87 | 0.15 | 11865 |
| 2026-07-21 | NBIX | 178.28 | 0.87 | 0.07 | 11906 |
| 2026-07-22 | NBIX | 173.14 | 0.86 | 0.19 | 11978 |
| 2026-07-23 | NBIX | 174.03 | 0.86 | 0.09 | 12033 |
| 2026-07-24 | NBIX | 175.37 | 0.86 | 0.03 | 12040 |
| 2026-07-27 | NBIX | 176.99 | 0.85 | 0.14 | 12080 |
| 2026-07-28 | NBIX | 182.83 | 0.85 | 0.07 | 12081 |
| 2026-07-29 | NBIX | 180.75 | 0.85 | 0.50 | 12257 |
| 2026-07-30 | NBIX | 180.18 | 0.88 | 0.05 | 12723 |
| 2026-07-31 | NBIX | 166.12 | 0.85 | 0.49 | 12977 |
| 2026-08-03 | NBIX | 166.22 | 0.84 | 0.23 | 13449 |
| 2026-08-04 | NBIX | 166.1 | 0.83 | 6.69 | 13505 |
| 2026-08-05 | NBIX | 161.44 | 0.90 | 6.32 | 14044 |
| 2026-08-06 | NBIX | 159 | 1.00 | 0.51 | 14742 |
| 2026-08-07 | NBIX | 163.38 | 1.01 | 1.00 | 14739 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-14 | NBIX | 172.05 | 32.6 | 171.9 | 10.24 |
| 2026-07-15 | NBIX | 172.08 | 32.6 | 184.4 | 10.24 |
| 2026-07-16 | NBIX | 171.44 | 32.6 | 180.4 | 10.24 |
| 2026-07-17 | NBIX | 170.78 | 35.0 | 179.5 | 10.20 |
| 2026-07-20 | NBIX | 172.97 | 35.0 | 197.0 | 10.20 |
| 2026-07-21 | NBIX | 178.85 | 17.2 | 219.3 | 9.93 |
| 2026-07-22 | NBIX | 172.70 | 17.2 | 147.6 | 9.93 |
| 2026-07-23 | NBIX | 174.16 | 17.2 | 193.0 | 9.93 |
| 2026-07-24 | NBIX | 175.67 | 17.8 | 193.9 | 9.95 |
| 2026-07-27 | NBIX | 176.41 | 17.8 | 187.9 | 9.95 |
| 2026-07-28 | NBIX | 182.78 | 17.8 | 221.5 | 9.95 |
| 2026-07-29 | NBIX | 180.88 | 17.8 | 173.1 | 9.95 |
| 2026-07-30 | NBIX | 185.81 | 17.8 | 212.9 | 9.95 |
| 2026-07-31 | NBIX | 166.74 | 19.8 | 84.5 | 9.96 |
| 2026-08-03 | NBIX | 166.29 | 19.8 | 106.2 | 9.96 |
| 2026-08-04 | NBIX | 166.29 | 19.8 | 106.2 | 9.96 |
| 2026-08-05 | NBIX | 161.47 | 24.3 | -84.7 | 10.10 |
| 2026-08-06 | NBIX | 159.82 | 24.3 | -70.5 | 10.10 |
| 2026-08-07 | NBIX | 163.35 | 24.3 | -44.1 | 10.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-14 | NBIX | -19.75 | 0.84 | 5.60 |
| 2026-07-15 | NBIX | -19.75 | 0.84 | 5.60 |
| 2026-07-16 | NBIX | -19.75 | 0.84 | 5.60 |
| 2026-07-17 | NBIX | -19.75 | 0.84 | 5.60 |
| 2026-07-20 | NBIX | -19.75 | 0.93 | 5.60 |
| 2026-07-21 | NBIX | -18.39 | 0.93 | 5.60 |
| 2026-07-22 | NBIX | -18.39 | 0.93 | 5.60 |
| 2026-07-23 | NBIX | -18.39 | 0.93 | 5.60 |
| 2026-07-24 | NBIX | -18.39 | 0.93 | 5.60 |
| 2026-07-27 | NBIX | -18.30 | 1.14 | 5.40 |
| 2026-07-28 | NBIX | -18.30 | 1.14 | 5.40 |
| 2026-07-29 | NBIX | -18.30 | 1.14 | 5.40 |
| 2026-07-30 | NBIX | -18.30 | 1.14 | 5.40 |
| 2026-07-31 | NBIX | -18.35 | 1.14 | 5.40 |
| 2026-08-03 | NBIX | -18.35 | 1.19 | 5.40 |
| 2026-08-04 | NBIX | -18.43 | 1.19 | 5.40 |
| 2026-08-05 | NBIX | -18.27 | 1.19 | 5.34 |
| 2026-08-06 | NBIX | -18.27 | 1.19 | 5.34 |
| 2026-08-07 | NBIX | -18.27 | 1.19 | 5.34 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.85
Avg. EPS Est. Current Quarter
2.7
Avg. EPS Est. Next Quarter
2.82
Insider Transactions
-18.27
Institutional Transactions
1.19
Beta
0.38
Average Sales Estimate Current Quarter
1044
Average Sales Estimate Next Quarter
1084
Fair Value
163.34
Quality Score
85
Growth Score
100
Sentiment Score
10
Actual DrawDown %
12.2
Max Drawdown 5-Year %
-42.9
Target Price
211.77
P/E
23.94
Forward P/E
16.68
PEG
0.43
P/S
4.92
P/B
4.49
P/Free Cash Flow
20.46
EPS
6.83
Average EPS Est. Cur. Y
10.1
EPS Next Y. (Est.)
12.18
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
20.91
Relative Volume
0.76
Return on Equity vs Sector %
-8.2
Return on Equity vs Industry %
12.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-0.09
EBIT Estimation
-44.1
◆
NBIX
Healthcare
$163.41
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.6
Range 1M
19.6%
Sup Dist
3.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
53.7%
EPS NY
36.4%
52W%
65.3%
Long-Term Value
Quality companies, undervalued
STRONG
🟢 BUY
+86.4% upside
Upside
+86.4%
Quality
85
MoS
0%
NBIX — P/E HistoricalBiotechnology
Neurocrine Biosciences, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2500
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
NBIX
Latest News
—
Caricamento notizie per NBIX…
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading